Dominantly inherited mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common causes of familial Parkinson's disease (PD) and LRRK2 polymorphisms are associated with increased risk for idiopathic PD. However, the molecular mechanisms by which these mutations cause PD remain uncertain. In vitro studies indicate that disease-linked mutations in LRRK2 increase LRRK2 kinase activity and LRRK2-mediated cell toxicity. Identifying LRRK2-interacting proteins and determining their effects on LRRK2 are important for understanding LRRK2 function and for delineating the pathophysiological mechanisms of LRRK2 mutations. Here we identified a novel protein, F-box and leucine-rich repeat domain-containing protein 18 (Fbxl18) that physically associates with LRRK2. We demonstrated that Fbxl18 is a component of a Skp1-Cullin1-F-box ubiquitin ligase complex that regulates the abundance of LRRK2 by selectively targeting phosphorylated LRRK2 for ubiquitination and proteasomal degradation. Knockdown of endogenous Fbxl18 stabilized LRRK2 abundance while protein kinase C activation enhanced LRRK2 degradation by Fbxl18. Dephosphorylation of LRRK2 blocked Fbxl18 association with LRRK2. Taken together, we have identified potential mechanisms for LRRK2 regulation by kinase signaling pathways. Furthermore, Fbxl18 prevented caspase activation and cell death caused by LRRK2 and PD-linked mutant LRRK2. This reveals novel targets for developing potential therapies for familial and idiopathic PD.
Introduction
Parkinson's disease (PD) is a progressive neurodegenerative movement disorder clinically characterized by bradykinesia, gait disturbances, resting tremor, muscular rigidity, and postural instability. After Alzheimer's disease, PD is the next most common neurodegenerative disease. Some cases of PD (5-10%) are genetically inherited, and mutations in several genes have been causally linked to familial PD (Farrer, 2006; Hardy et al., 2006) . Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of PD and polymorphisms in LRRK2 are associated with increased risk for sporadic PD (Cookson and Bandmann, 2010; Wu et al., 2012; Yue, 2009) .
Despite the importance of LRRK2 in PD, the normal cellular function of LRRK2 and pathogenic mechanisms of LRRK2 mutations remain inadequately understood. LRRK2 is a large multi-domain protein consisting of 2527 amino acids with an apparent molecular weight of approximately 285 kDa. LRRK2 contains both active kinase and GTPase domains as well as protein-protein interaction motifs including a leucine-rich repeat (LRR) domain and a WD40 domain (Li et al., 2007; Mata et al., 2006; Webber and West, 2009) . In vitro studies indicate that diseaselinked LRRK2 mutations increase LRRK2 kinase activity and LRRK2-mediated cell toxicity (Greggio et al., 2006; Smith et al., 2006; West et al., 2007) . Identifying LRRK2-interacting proteins and determining their effects on LRRK2 are important for understanding LRRK2 function and for delineating the pathophysiological mechanisms of LRRK2 mutations. We and others have identified LRRK2-interacting proteins using a variety of methods, such as yeast two-hybrid screening, co-immunoprecipitation assays and various proteomic approaches (Dachsel et al., 2007; Ding and Goldberg, 2009; Hsu et al., 2010; Ko et al., 2009; Li et al., 2011; Smith et al., 2005; Wang et al., 2008) .
Here we report the identification of a novel LRRK2-associated protein, F-box and leucine-rich repeat domain-containing protein 18 (Fbxl18) that binds to LRRK2 and functions as an E3 ubiquitin ligase. Fbxl18 is a member of a family of sixty-eight known human genes encoding F-box motifs (Jin et al., 2004) . It has been reported that Fbox proteins function as receptors that recruit phosphorylated proteins to Skp1-Cullin1-F-box (SCF) ubiquitin ligase complexes that regulate protein abundance by coupling protein kinase signaling pathways to proteasomal degradation (Cardozo and Pagano, 2004; Lechner et al., 2006; Skowyra et al., 1997) . Furthermore, F-box proteins are altered in many diseases, such as cancer and rheumatoid arthritis, and have been proposed as attractive therapeutic targets because of their crucial Neurobiology of Disease 98 (2017) 122-136 
